Accelera Recognised as Key Partner in the Development of a New Therapy
NERVIANO, Italy, June 27 /CNW/ - The development of fexinidazole for the
treatment of African trypanosomiasis, commonly known as "sleeping sickness",
by DNDi (Drugs for Neglected Diseases initiative), along with Accelera, a
business unit of Nerviano Medical Sciences (NMS), is to be honoured as one of
DNDi's Success Stories of the Year. The award will be conferred today in New
York, at the prestigious headquarters of the New York Academy of Sciences,
during the first annual Stakeholders' Meeting of DNDi. Accelera is recognised
as DNDi's key partner in the non-clinical development of fexinidazole.
"We are proud to receive this recognition," comments Dr. Marco Brughera -
Vice President of Accelera - "and happy to be able to contribute to improving
the health of populations living in the poorest countries. We were delighted
to be selected from among several international Contract Research
Organisations (CROs) to be DNDi's partner of choice for characterizing the
preclinical profile of fexinidazole."
"The preclinical work to support the profiling of fexinidazole started at
Accelera more than one year ago," Dr Brughera points out, "and included a
series of in vitro and preliminary activities followed by a full package of
tolerability and safety studies as requested by Regulatory Authorities. The
results obtained have allowed DNDi to proceed to the next stage of
fexinidazole's development, with a quick registration being a primary goal."
Accelera carries out preclinical development activities for molecules
targeting various different therapeutic classes, including collaborations
aimed at defining therapeutic solutions for other "neglected diseases," such
as malaria, visceral leishmaniasis, African trypanosomiasis, and Chagas'
"Our pride in this recognition is twofold: on the one hand there is the
satisfaction of being an active collaborator within such international
projects, and on the other the knowledge that we have been able to make our
contribution to a humanitarian initiative like that of DNDi," continues
Giampiero Duglio, Managing Director of NMS.
About Accelera (http://www.accelera.info)
Accelera, BU of Nerviano Medical Sciences, is a premium tier Contract
Research Organization (CRO), working and collaborating with pharmaceutical and
biotechnology companies around the world. Committed to offering the highest
levels of service throughout drug discovery and development, our expertise can
make a difference, right from the start.
About Nerviano Medical Sciences - NMS (http://www.nervianoms.com)
NMS is a research based company dedicated to the discovery and
development of breakthrough new chemical entities (NCEs) for the treatment of
cancer. NMS was incorporated in May 2004 as a spin-off from Pfizer and is
wholly owned by the Rome-based Congregazione dei Figli dell'Immacolata
For further information:
For further information: Accelera (Nerviano Medical Sciences), Maria
D'Acquino, mob +39-335-1863052, email@example.com